Aerovate Therapeutics (AVTE) Earnings Date, Estimates & Call Transcripts $10.00 +0.07 (+0.70%) As of 10/24/2025 Add Compare Share Share Earnings Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Aerovate Therapeutics Earnings Summary Aerovate Therapeutics posted Q4 2024 earnings on April 25, 2025, reporting an EPS of -$3.15, which topped analysts' consensus estimates of -$10.50 by $7.35. With a trailing EPS of -$1.70, Aerovate Therapeutics' earnings are expected to grow next year, from ($2.64) to ($0.84) per share. Upcoming Earnings DateNov. 10Before Market OpensEstimatedConsensus EPS (Apr. 25) -$10.50 Actual EPS (Apr. 25) -$3.15 Beat By $7.35 Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Annual Report (10-K)AVTE Upcoming EarningsAerovate Therapeutics' next earnings date is estimated for Monday, November 10, 2025, based on past reporting schedules. Powered by Get Aerovate Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataAVTE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Aerovate Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$14.35-$14.35-$14.35Q2 20251-$10.85-$10.85-$10.85Q3 20251-$8.75-$8.75-$8.75Q4 20251-$5.95-$5.95-$5.95 Aerovate Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/10/2025(Estimated)--------4/25/2025Q4 2024-$10.50-$3.15+$7.35-$0.09--3/27/2025Q4 2024-$6.65-$6.65--$0.19--11/12/2024--$20.65-$19.60+$1.05-$0.56--8/12/2024Q2 2024-$26.60-$30.10 -$3.50-$0.86--5/13/2024Q1 2024-$25.90-$29.05 -$3.15-$0.83--3/25/2024Q4 2023-$23.80-$25.90 -$2.10-$0.74--11/13/2023Q3 2023-$24.50-$24.85 -$0.35-$0.71-- Aerovate Therapeutics Earnings - Frequently Asked Questions When is Aerovate Therapeutics' earnings date? Aerovate Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 10th, 2025 based off last year's report dates. Learn more on AVTE's earnings history. Did Aerovate Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aerovate Therapeutics (NASDAQ:AVTE) reported ($3.15) earnings per share (EPS) to beat the analysts' consensus estimate of ($10.50) by $7.35. Learn more on analysts' earnings estimate vs. AVTE's actual earnings. How much profit does Aerovate Therapeutics generate each year? Aerovate Therapeutics (NASDAQ:AVTE) has a recorded net income of -$75.52 million. AVTE has generated -$1.70 earnings per share over the last four quarters. What is Aerovate Therapeutics' EPS forecast for next year? Aerovate Therapeutics' earnings are expected to grow from ($2.64) per share to ($0.84) per share in the next year. More Earnings Resources from MarketBeat Related Companies Oruka Therapeutics Earnings Amphastar Pharmaceuticals Earnings Dianthus Therapeutics Earnings Collegium Pharmaceutical Earnings Xencor Earnings Kodiak Sciences Earnings Tango Therapeutics Earnings Phathom Pharmaceuticals Earnings Rapport Therapeutics Earnings ARS Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings This page (NASDAQ:AVTE) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts